The upgrade in the price target by a reputable analyst like Anupam Rama from JP Morgan is a strong positive signal for Syndax Pharmaceuticals. It suggests a bullish outlook on the stock's future performance, likely due to underlying strengths in the company's operations, pipeline, or market position. This kind of endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.